Karyopharm Therapeutics
KPTI
52 hedge funds and large institutions have $19.5M invested in Karyopharm Therapeutics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 20 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
4% more funds holding
Funds holding: 50 → 52 (+2)
2% more capital invested
Capital invested by funds: $19M → $19.5M (+$444K)
16.75% less ownership
Funds ownership: 51.07% → 34.32% (-17%)
26% less call options, than puts
Call options by funds: $5.74M | Put options by funds: $7.74M
65% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$190K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$135K |
| 3 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$82.9K |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
+$78.4K |
| 5 |
State Street
Boston,
Massachusetts
|
+$70.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.38M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.11M |
| 3 |
EP
Eversept Partners
New York
|
-$1.11M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$906K |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$810K |
KPTI Hedge Fund Activity: Q3 2025 in Review
52 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2025, worth a combined $19.5M — up 2.3% from $19M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new KPTI positions and 5 closed out — a net gain of 2 holders — while 7 added to existing stakes and 20 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $190K. The largest seller was JP Morgan Chase, cutting an estimated $1.38M.
- 52 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2025, up from 50 in Q2 2025.
- Funds reported $19.5M of Karyopharm Therapeutics stock for Q3 2025, up 2.3% quarter-over-quarter.
- 7 funds opened new Karyopharm Therapeutics positions in Q3 2025 and 5 closed out, a net change of +2 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2025 was Susquehanna International Group, an estimated $190K added.
- The largest Karyopharm Therapeutics seller in Q3 2025 was JP Morgan Chase, an estimated $1.38M sold.
Based on aggregated 13F filings for Q3 2025.